The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin by Ordóñez, José Luis et al.
Oncotarget18875www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 22
The PARP inhibitor olaparib enhances the sensitivity of Ewing 
sarcoma to trabectedin
José Luis Ordóñez1,4,*, Ana Teresa Amaral1,4,*, Angel M. Carcaboso2, David Herrero-
Martín3, María del Carmen García-Macías4, Vicky Sevillano4, Diego Alonso4, Guillem 
Pascual-Pasto2, Laura San-Segundo4, Monica Vila-Ubach2, Telmo Rodrigues4, 
Susana Fraile4, Cristina Teodosio4, Agustín Mayo-Iscar5, Miguel Aracil6, Carlos 
María Galmarini6, Oscar M. Tirado3, Jaume Mora2 and Enrique de Álava1,4
1 Laboratory of Molecular Pathology- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/
Universidad de Sevilla, Seville, Spain
2 Developmental Tumor Biology Laboratory. Preclinical Therapeutics and Drug Delivery Research Program, Hospital Sant Joan 
de Deu Barcelona, Spain
3 Sarcoma Research Group, Laboratori d’Oncología Molecular, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), 
L’Hospitalet de Llobregat, Barcelona, Spain
 4 Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer/ Consejo Superior de Investigaciones 
Científicas-Universidad de Salamanca, Salamanca, Spain
5 Statistics and Operations Research Department-University of Valladolid, Spain
6 Cell Biology and Pharmacogenomics Department, Pharmamar, Madrid, Spain
* These authors have contributed equally to this work
Correspondence to: José Luis Ordóñez García, email: jordonez-ibis@us.es
Correspondence to: Enrique de Álava, email: enrique.alava.sspa@juntadeandalucia.es
Keywords: ewing sarcoma, PARP inhibitor, trabectedin, DNA damage, PDX models
Received: March 13, 2015 Accepted: May 13, 2015 Published: May 27, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
AbstrAct
Recent preclinical evidence has suggested that Ewing Sarcoma (ES) bearing 
EWSR1-ETS fusions could be particularly sensitive to PARP inhibitors (PARPinh) in 
combination with DNA damage repair (DDR) agents. Trabectedin is an antitumoral 
agent that modulates EWSR1-FLI1 transcriptional functions, causing DNA damage. 
Interestingly, PARP1 is also a transcriptional regulator of EWSR1-FLI1, and PARPinh 
disrupts the DDR machinery. Thus, given the impact and apparent specificity of both 
agents with regard to the DNA damage/DDR system and EWSR1-FLI1 activity in 
ES, we decided to explore the activity of combining PARPinh and Trabectedin in in 
vitro and in vivo experiments. The combination of Olaparib and Trabectedin was 
found to be highly synergistic, inhibiting cell proliferation, inducing apoptosis, and 
the accumulation of G2/M. The drug combination also enhanced γH2AX intranuclear 
accumulation as a result of DNA damage induction, DNA fragmentation and global DDR 
deregulation, while EWSR1-FLI1 target expression remained unaffected. The effect of 
the drug combination was corroborated in a mouse xenograft model of ES and, more 
importantly, in two ES patient-derived xenograft (PDX) models in which the tumors 
showed complete regression. In conclusion, the combination of the two agents leads 
to a biologically significant deregulation of the DDR machinery that elicits relevant 
antitumor activity in preclinical models and might represent a promising therapeutic 
tool that should be further explored for translation to the clinical setting. 
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INtrODUctION
ES is an aggressive developmental mesenchymal 
tumor [1]. As a result of multimodal therapy, including 
strategies from traditional chemotherapeutic agents, 
radiotherapy, and surgery, the current cure rate of ES 
patients with localized disease is 70% [2, 3]. However, 
the survival rate for patients with relapsed, multifocal/
metastatic disease is still less than 20%, mainly due to 
development of drug resistance. Recently, a retrospective 
study by our group revealed the prognostic value of 
chromosome 1 gain (1qG) in ES [4]. Within the up-
regulated candidate genes identified in 1qG ES, a 
particularly interesting gene was found: poly (ADP-ribose) 
polymerase-1 (PARP1) [4]. Other studies have recently 
described that PARP1 plays an important role in tumors 
bearing ETS fusions, such as prostate cancer and ES [5, 6]. 
PARP proteins play a relevant role in the regulation 
of the cell cycle, apoptosis, genomic stability, chromatin 
remodeling, transcription, tumor growth and even the 
induction of chromosomal translocations. PARP1 has 
been shown to act as a transcriptional regulator of 
EWSR1-FLI1, which has triggered interest in testing 
PARPinh in ES [6, 7]. However, the best known activity 
of PARP proteins is related to the mechanisms of DDR, 
especially regarding the Base Excision repair (BER) 
pathway [8]. In brief, the BER is the main pathway 
responsible for repairing single-strand breaks (SSB) of 
DNA. In the absence of an effective BER mechanism, 
SSB accumulation results in Double-Strand Breaks (DSB), 
the most lethal form of DNA damage. Globally, when the 
DDR machinery fails this produces both an increase in the 
frequency of acquired mutations and genomic instability 
and both these determine the appearance, evolution and 
progression of tumors. In fact, an active DDR machinery 
is essential for the physiology of the cell, ensuring its 
survival, and is an important mechanism of resistance 
to cytotoxic agents. Accordingly, the inhibition of the 
DDR in tumor cells provides an excellent therapeutic 
opportunity [9]. Inhibitors of the DDR machinery have 
been used successfully against tumor cells in monotherapy 
or combined with other agents in order to sensitize tumor 
cells to the cytotoxic activity of other drugs. Within this 
large group of drugs, to date PARPinh represents one of 
the most promising subgroup of agents [8, 9]. In this sense, 
it has recently been reported that ES cells are defective 
in DNA breakage repair systems, being very sensitive to 
PARPinh in combination with DNA damaging-drugs [10]. 
Trabectedin is a marine-derived compound with 
proven antitumor activity against several types of 
neoplasms, including sarcomas, ovarian, and breast 
cancer, among others, by inducing DNA breaks. Clinical 
trials have shown that Trabectedin is particularly active 
in sarcomas bearing translocations, namely myxoid 
Liposarcoma (ML), ES and Synovial Sarcoma [11, 12]. 
In ES, Grohar et al. showed that, similarly to the previous 
observation in ML, Trabectedin interferes directly 
with the chimeric protein EWSR1-FLI1 [12]. In fact, 
treatment with Trabectedin specifically deregulates the 
transcriptional activity of the chimeric protein [12-14]. 
Given the impact and apparent specificity of 
PARPinh and Trabectedin with regard to the DNA 
damage/DDR system and EWSR1-FLI1 activity in ES, 
we decided to explore the effects of the combination 
through a series of in vitro and in vivo studies. We report 
that the combination of Trabectedin and Olaparib is highly 
synergistic in ES cell lines, inducing major DNA damage 
in vitro and in vivo and causing a clinically significant 
degree of tumor regression in PDX) models of ES. 
rEsULts
Es cells are especially sensitive to olaparib, which 
induces G2/M accumulation independently of the 
1q status
Initially, we checked the status of PARP1 in a 
panel of ES cell lines (Supplementary Table S1) using 
a home-made fluorescence in situ hybridization (FISH) 
probe specific for PARP1. We observed that ES cell 
lines previously described as 1qG in fact showed an 
amplification of PARP1 by FISH (Figure 1A). cDNA 
analysis showed that all ES cell lines express PARP1 with 
different mRNA levels (Figure 1B). Also, using a specific 
antibody for PARP1, by Western-blot we observed that 
all cell lines studied expressed PARP1 at similar levels, 
independently of the 1qG status, (Figure 1C-1D).
We studied the sensitivity of ES cell lines to a group 
of PARPinh, including Olaparib, Veliparib and Iniparib. 
Olaparib was more active in inhibiting proliferation than 
the other two drugs assayed, with lower IC50 levels at 72 
hours of exposure (high nM-low μM range, with a median 
of 1.995 ± 0.46μM). Veliparib was the second most 
effective agent, with IC50 levels of proliferation in the μM 
range, with a median of 14.14±2.75μM (approximately 7 
fold higher than Olaparib). Finally, Iniparib was the least 
effective agent, showing IC50 levels also in the μM range 
but with a median of 74.95 ± 5.02μM (approximately 
38-fold higher than Olaparib) (Figure 2A). Interestingly, 
we observed that after 72 hours of exposure to Olaparib 
IC50 levels were higher than those obtained after 6 days 
of treatment (Supplementary Figure S1A). Given that 
PARP1 is located on chromosome 1q, and in view of our 
previous results describing some ES tumors and cell lines 
with 1qG, we searched for a correlation between the status 
of 1q [Gained or Normal (N)] and Olaparib sensitivity 
(Supplementary Figure S1B). We observed a trend towards 
a higher sensitivity of 1qG cell lines to Olaparib, but it 
was not statistically significant, probably due to the low 
number of cell lines analyzed (Mann Whitney U test, p 
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> 0,05). The correlation between the status of p53 (wild-
type or mutated) and the sensitivity to Olaparib was not 
statistically significant either (Mann Whitney U test, p > 
0.05) (Supplementary Figure S1C). We also studied the 
effects of Olaparib on the cell cycle profile using two ES 
cell lines, A673 (1qN) and A4573 (1qG) (Figure 2B). Both 
cell lines showed G2/M accumulation after treatment, 
even at low doses of Olaparib (Figure 2B). 
the combination of olaparib and trabectedin is 
highly synergistic in Es cell lines
Having observed that Olaparib was much more 
cytotoxic than the other PARPinh, we studied the effects 
of the combination of Olaparib with Trabectedin. ES cell 
lines (n = 10) were exposed to different combinations 
of both agents at a constant ratio of 1:20.000 
(Trabectedin:Olaparib) for 72 hours and Combination 
Indices (CIs) were determined according to [15, 16]. 
Interestingly, synergistic effects were observed in all but 
two cell lines (Table 1). We then studied the effects of 
this drug combination on apoptosis induction via caspase 
-3 and -7 activation after 48 hours of drug exposure as 
well as cell cycle effects after 24 hours of treatment in 
two cell lines, RM82 and TC71. We observed that the 
drug combination (250pM of Trabectedin and 5μM of 
Olaparib) increased the apoptotic rate in the TC71 cell line 
(Supplementary Figure S2A). In agreement with this, we 
observed cleaved PARP accumulation after treatment with 
the combination, especially at 24 hours, in the TC71 cell 
line (Supplementary Figure S2B). Furthermore a G2/M 
accumulation and the elimination of the G0/G1 phase were 
also observed after treatment with the drug combination 
(Supplementary Figure S2C). In the RM82 cell line, 
treatment with the drug combination only induced mild 
apoptosis (Supplementary Figure S2A). By contrast, no 
effects on cell migration after 72 hours of drug exposure 
were observed (Supplementary Figure S3). 
Figure 1: PArP1: gene status, mrNA and protein expression. A. FISH of PARP1. ES cell lines previously described as 1qG 
showed extra-copies of PARP1 (CADO and TC71 cell lines) whereas A673, described as 1qN, showed only two copies of PARP1 by FISH. 
Green and red dots represent PARP1 gene copies and 1q centromeres, respectively. Arrows also indicate the green dots (PARP1 gene 
copies). b. q-RT-PCR shows that PARP1 expression is heterogeneous among the ES cell lines studied. SJRH also express PARP1 at similar 
levels to the ES cell lines. A4573 (1qG) and A673 (1qN) are the cell lines with the highest expression of PARP1. The MCF7 breast cancer 
cell line was used as a positive control. c. Western blotting showed that ES cell lines express PARP1 under normal conditions. Here, breast 
cancer cell lines (MCF7 and MD-MB 23) were used as positive controls. D. Quantification of PARP1 protein levels with respect to β-actin 
expression using Image J software. 
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the combination of olaparib and trabectedin 
enhances DNA damage while EWsr1-FLI1 
activity is not deregulated
DNA damage induction was evaluated by testing 
for the presence of intranuclear foci of γH2AX and 
53BP1 after short (8 hours) and long (24 hours) drug 
exposures. Initially, cells were treated with Trabectedin 
(250pM) and/or Olaparib (5μM) for 8 hours. Trabectedin 
induced a stronger DSB accumulation than that 
induced by Olaparib alone (Student´s t-test, p < 0.05). 
Nevertheless, the combination of both agents resulted 
in a clear enhancement of DSB formation (Figure 3A 
and Supplementary Figure S4). After 24 hours of drug 
exposure, the drug combinations resulted in cumulative 
effects of DNA damage through the induction of DSB, 
even at the lowest drug concentrations used (125pM of 
Trabectedin and 2.5 μM) (Figure 3B). Interestingly, the 
combination did not affect EWSR1-FLI1 transcriptional 
activity (Supplementary Figure S5A).
Moreover, DNA fragmentation assays revealed that 
both drugs were able to generate enough damage to induce 
DNA fragmentation (Figure 3C and Supplementary Figure 
S5B). 
Olaparib and/or trabectedin induce deregulation 
of the DDr machinery
After demonstrating that the combination of 
Olaparib and Trabectedin induced DNA damage by 
DSB accumulation, we next analyzed the regulation 
of the DDR machinery in TC71 cells. To this end, we 
table 1: Proliferation assays show that the combination of Olaparib and trabectedin is synergistic in 
all Es cell lines with the exception of A4573 and WE68, where the cIs are almost additive (values close 
to 1).
Cell lines CI Effects
RDES 0.73 Synergism
WE68 0.92 Nearly additive
STAET-2.1 0.49 Synergism
RM82 0.69 Synergism
TC71 0.4 Synergism
SK-N-MC 0.008 Synergism
CADO 0.4 Synergism
A673 0.77 Synergism
A4573 0.93 Nearly additive
STAET-1 0.64 Synergism
SJRH 0.11 Synergism
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used low-density arrays (DDR PCR Array; PAHS-042Z, 
Qiagen). After 16.5 hours of treatment with Olaparib 
(5µM) and/or Trabectedin (250pM), RNA was extracted 
and the changes in the mRNA levels regarding DNA 
damage induction and DDR mechanisms were analyzed. 
Treatment with Trabectedin caused an overexpression of 
homologuous recombination (HR)-related genes such as 
BRCA1, BRCA2, RAD18, RAD52 and BRIP1 (BRCA1/2-
associated molecule) as well as POLD3 (DNA polymerase 
delta subunit 3); NEIL3 (nei endonuclease VIII-like 3) 
involved in the BER pathway; RFC1 (replication factor 
C), which is involved in GC-NER DSB repair; OGG1; 
XRCC1, involved in DNA- and protein-binding and 
strand-break correction, and UNG, a DNA glycosylase 
involved in the BER pathway (Supplementary Tables 
S2, S3 and Supplementary Figure S6). Treatment with 
Olaparib induced the expression of the HR-related 
genes EXO1, RAD54L, RAD51B and RAD18, together 
with BRIP1, RFC1, PARP3, XRCC, POLD3 and PARP3 
(Supplementary Tables S2, S3 and Supplementary Figure 
S7). The global deregulation of the DNA damage and 
repair machinery was clearly observed with the combined 
treatment, where the HR genes RAD54L, EXO1, PARP2, 
BRCA1, BRCA2, RAD18, RAD50, RAD51 and RPA1 
were overexpressed (Supplementary Table S2, S3 and 
S4). Changes in expression in this array were highly 
Figure 2: PArPinh activity: proliferation and cell cycle analysis. A. IC50 of proliferation after 72 hours of drug exposure. ES 
cell lines and the SJRH cell line were more sensitive to Olaparib than to the other agents b.. Cell cycle analysis on A673 (1qN) and A4573 
(1qG) after treatment with two different concentrations of Olaparib. 
Oncotarget18880www.impactjournals.com/oncotarget
correlated with DSB repair by the NER pathway (p value: 
1.02E-23), the NHEJ pathway (p-value: 1,81E-23), the 
HR pathway (p-value: 4,41E-18) and the related BRCA1 
and BRCA2 pathways (p-values 4,52E-18 and 2,24E-17) 
(Supplementary Table S4). Ingenuity Pathway Analysis 
(IPA) discriminated the most significant upregulated and 
downregulated molecules involved in the major DNA 
damage pathways. The combination treatment induced a 
stronger deregulation of the molecules involved in these 
pathways (Figure 4).
the drug combination reduces tumor growth 
dramatically in an in vivo model
In view of the results obtained in the in vitro 
study, we decided to test the antitumor effects of the 
Trabectedin and Olaparib combination in a NOD/SCID 
mouse xenograft model of ES. Xenografts were generated 
by subcutaneous injection of TC71 cells. Animals were 
randomized in 5 groups and treated for three weeks: 1) 
Control group: drug vehicles; 2) Trabectedin group: 
Trabectedin alone (0.15mg/Kg IV once a week five 
times per week); 3) Olaparib group: Olaparib (100mg/
Kg BID IP five times per week); 4) Combination1 group: 
Olaparib alone (100mg/Kg BID IP five times per week) 
for 1 week, and Olaparib plus Trabectedin (0.15mg/
Kg IV once a week) for the second and third week; 5) 
Combination 2 group: Olaparib (100mg/Kg BID IP) plus 
Trabectedin (0.15mg/Kg IV once a week). After three 
weeks of treatment, the mice were sacrificed and tumors 
were extracted, weighed, and evaluated by histopathology.
The evolution of tumor volume after randomization 
(see Material and Methods section) and tumor weight 
Figure 3: DNA damage induction studies. (A and B) Images represent data obtained in the study of induction of DSB evaluated by 
the presence of intranuclear γH2AX and 53BP1 foci after treatment with Trabectedin and/or Olaparib in the TC71 cell line. A. Short-term 
DNA damage induction (8 hours of drug exposure). The combination of Trabectedin and Olaparib led to an increased presence of pH2AX 
and 53BP1 foci in the nucleus. b. Long-term DNA damage induction (24 hours of drug exposure). c. Image represents data obtained in 
the fragmentation assays after 24 – 48 hours of drug exposure. Although DNA fragmentation was also observed in the control (DMSO), 
Trabectedin and/or Olaparib induced higher DNA fragmentation. Here, DSB-induced DNA fragmentation can be seen by the presence 
of a smear just below the intact DNA (represented by *), whereas the smaller fragments (represented by **) are produced exclusively 
by apoptosis induction. In all cases, combination 1 refers to 125pM Trabectedin and 2.5µM Olaparib; combination 2 refers to 250pM 
Trabectedin and 5µM. Olaparib.
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at the end of the study (18 days after the treatments had 
started), shown in Figure 5A and 5B respectively, were 
evaluated in all groups. Although Trabectedin and Olaparib 
alone were able to reduce tumor volume as compared with 
the control groups, these differences were not statistically 
significant (Mann-Whitney U-test, p > 0.05). However, 
the combination of both drugs dramatically reduced 
tumor growth (Mann-Whitney U-test p < 0.05). In fact, 
the tumors were smaller at the end of the study than they 
were at the moment of randomization, before treatment.
Histopathological analysis of representative 
tumors from each group of mice revealed significant 
morphological changes. The drug-induced morphological 
changes were characterized by the presence of ES cells 
with conspicuous nucleoli, granular chromatin, an 
enlarged cytoplasm and vacuoles (Figure 5C). Necrosis 
was observed in the animals of all groups, although it 
was significantly more extensive in the animals treated 
with the combination of drugs (t-test, p < 0.05) (Figure 
5C and Supplementary Figure S8A). The necrotic/
viable tumor ratio was much higher in the treated groups 
(Supplementary Figure S8A, B). No signs of toxicity were 
observed with the combination treatment. 
the drug combination increases DNA damage 
induction and DDr activation in the in vivo model
A representative number of tumor areas from 
tumors of all groups in the in vivo study were evaluated 
by Immunoflorescence (IF)/ Immunohistochemstry 
(IHC) in order to assess the effects of the treatments. To 
quantify the findings, we used the Ariol Image analysis 
system (Olympus). The following parameters were 
studied: apoptosis (fragmentation-late apoptosis and PARP 
cleavage) (TUNEL assay and cleaved PARP); proliferation 
(Ki67), DNA damage induction (γH2AX) and DDR 
activation (BRCA2).
The proliferation index was higher in the controls 
as compared with all treated groups, and this was 
statistically significant (p < 0.05) (Figure 6, central panel 
A and Supplementary Figure S8B). These results are in 
agreement with the data from the TUNEL assays, where 
late apoptosis due to DNA fragmentation was mostly 
observed in representative tumor areas from animals 
treated with Trabectedin alone or in tumors from animals 
treated with the combination of drugs (Figure 6, upper 
Figure 4: Expression changes in DNA damage repair genes in Es cells from the tc71 cell line. Schematic representation of 
gene interactions in cells treated with the combination of Olaparib (5µM) and Trabectedin (250pM), obtained after performing IPA. Over-
expressed genes are highlighted in red, and the down-regulated genes are highlighted in green. The central genes involved in HR machinery 
are highlighted in color, such as BRAC1, EXO1, RAD51 and BRCA2, among others. 
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panel A). PARP cleavage was observed in tumors from 
the Olaparib group (Figure 6, lower panel A).
Interestingly, DNA damage induction as assessed by 
pH2AX staining was much higher in animals from both 
combination groups (mean Combination 1: 60.975%, 
mean Combination 2 group: 68.09%) as compared with 
controls (mean 0.85%); Trabectedin (mean 11.13%) 
and Olaparib (mean 1.04%) (p < 0.05) (Figure 6B and 
Supplementary Figure S8C, S9). This observation 
correlated well with the overexpression of the HR effector 
molecule, BRCA2. Treatment with the combination of 
Olaparib and Trabectedin resulted in a much more intense 
and diffuse staining of BRCA2, especially in combination 
2 (Combination1: mean 42.03%; Combination 2: mean 
76.79% vs. mean control group 11.9%) (Supplementary 
Figure S8D). Additionally, BRCA2 expression was diffuse 
and intense in the case of tumors from the Trabectedin 
group (mean 63.84%) (Figure 5C and Supplementary 
Figure S8D, S10). 
the trabectedin-olaparib combination induces 
complete tumor regression in PDX models
Because studies in PDX models are likely to be 
more predictive of patient response to treatment than 
conventional cell lines [17], we performed survival 
studies in two ES PDX models (HSJD-ES-004 and HSJD-
ES-006) established from patient biopsies at the Sant Joan 
de Déu Hospital (HSJD, Barcelona, Spain). The clinical 
characteristics of the patients and the molecular details 
of both tumor models are shown in Table 2. The tumor 
response at the end of treatment is shown in Table 3. The 
most remarkable finding was that the Olaparib-Trabectedin 
combination achieved complete response (CR) in 100% 
of the tumors of both PDX models. In contrast, Olaparib 
treatment alone led to progressive disease (PD) in 100% of 
the tumors. Trabectedin alone achieved CR in 88% of the 
HSJD-ES-004 tumors and CR in 78% of the HSJD-ES-006 
tumors. CRs in monotherapy were transient in most 
animals and did not persist until the end of the survival 
study (Figure 7A). In the HSJD-ES-004 model, the median 
survival of the controls was 14 days, as compared to 35 
table 2: Details of the Es PDX models.
Model 
code
source of 
biopsy1
Age at 
biopsy
Primary 
tumor
Age at 
diagnosis
Metastasis 
at 
diagnosis
Demography Fusion gene
stAG2 
mutation
p53
mutation
Patient 
status
HSJD-
ES-0042
Relapse. 
Metastasis 
in the 
mediastinum
18 y
T12 
vertebral 
body
10 y No Male, white EWSR1-FLI1 negative negative NED
3
HSJD-
ES-006
Relapse. 
Metastasis in 
the lung
14 y  Fibula 12 y No Male, white EWSR1-FLI1 negative negative AWD
4
1 Tumor tissue was collected with informed consent under an Institutional Review Board-approved protocol.
2 Further details on this PDX model are published in [21], coded  SJDES022-R.
3 No evidence of disease.
4 Alive with disease.
table 3: Es PDX models: response to treatment (day 21).
PDX Model treatment tumors (n) response
1
cr Pr sD PD
HSJD-ES-004
Control 10 0 0 0 10
Olaparib 9 0 0 0 9
Trabectedin 8 7 0 0 1
Combination 8 8 0 0 0
HSJD-ES-006
Control 10 0 0 0 10
Olaparib 10 0 0 0 10
Trabectedin 9 1 1 0 7
Combination 9 9 0 0 0
1 CR: Complete response (CR) was defined, as previously described in [34], as the disappearance of 
measurable tumor mass (<0.10 cm3) at the end of treatment (day 21); PR: Partial response (PR) was 
defined as a tumor volume regression ≥50% at the end of treatment (day 21) but with a measurable tumor 
size  (≥0.10 cm3); SD: Stable disease (SD) was defined as <50% regression from the initial volume and 
a ≤25% increase in initial volume at the end of treatment (day 21). PD: Progressive disease (PD) was 
defined as <50% regression from the initial volume and a >25% increase in the initial volume at the end 
of treatment (day 21). 
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days for the Olaparib group (p = 0.192), and 75 days for 
the Trabectedin group (p = 0.0 01). In the HSJD-ES-006 
model, the median survival of the controls was 11 days, 
as compared to 17 days for the Olaparib group (p < 0.05), 
and 35 days for the Trabectedin group (p = 0.001). The 
combination therapy extended survival significantly, up to 
a value greater than the evaluation period (80 days), when 
compared with the control mice (p < 0.05 for both models; 
Figure 7B).
DIscUssION
Trabectedin induces DNA damage and cellular 
death in vitro and interrupts EWSR1-FLI1-dependent 
transcription [12]. Additionally, ES cells are sensitive to 
PARPinh, which disrupt the DDR system of tumor cells 
[7, 10]. Furthermore, PARP1, the main PARPinh target, 
also acts as a transcriptional regulator of EWSR1-FLI1 
[6]. Accordingly, we formulated the hypothesis that 
the combination of Trabectedin with a PARPinh could 
interfere with the DDR system and might be able to 
inhibit EWSR1-FLI1, and could therefore be of interest as 
a therapeutic strategy. The results obtained in the present 
study support the clinical development of a combination 
of PARPinh with Trabectedin in ES. 
The relationship between PARP1 and ES has been 
documented for many years [18]. However, knowledge of 
the more specific and relevant role of this protein in ES 
is much more recent [6, 7]. Brenner et al. described that 
PARP1 interacts physically with EWSR1-FLI1 fusion, 
acting in a positive feed-back loop and hence regulating 
its own expression [6]. In a retrospective study, our group 
Figure 5: In vivo model using the tc71 cell line. A. Graphic representing the evolution of tumor growth in the different treatment 
groups. Tumor growth was clearly halted by the combination of Olaparib and Trabectedin (Combination2) and when Trabectedin began to 
be administered one week later (Combination 1). b. Graphic representation of mean tumor weights at the end of the study (18 days after 
treatment began to be administered) in each of the treatment groups. Tumor weight was clearly reduced, especially in the Combination 1 
and 2 groups. c. Representative pictures showing (in columns from left to right) tumors extracted and 4X and 60X H&E representative 
areas of the tumors from each treatment group respectively. In the second column some necrotic areas are indicated among areas of living 
cells (*). In the third column, the tumors in the control group show characteristic small round cells with a round nucleus, regular chromatin, 
a clear nucleolus, scant and rare cytoplasm and a high number of mitotic figures (white arrows). By contrast, the tumors in the treated 
groups, and, especially in the two combination groups, showed degenerate cells (black arrow), with a vacuolated and degenerate cytoplasm 
and apoptotic figures (black arrowhead). Comb 1 refers to Combination 1. Comb 2 refers to Combination 2. (* or # mean p < 0.05; *, Comb 
1 or Comb 2 vs. control; #Comb 1 or comb 2 vs. Olaparib alone or Trabectedin alone).
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has reported that 1qG was of prognostic significance in ES 
[4] and in the present study we show that 1qG is strongly 
linked to the upregulation of PARP1, among other genes 
[4]. 
The mechanism of action of PARPinh in cancer 
cells appears to be mainly related to the induction of 
DNA damage by the formation of irreparable SSB. 
These drugs are used in monotherapy in tumors with 
baseline molecular inactivation in some of the DDR 
system components, such as BRCA1/BRCA2 [19, 20]. 
The use of PARPinh in monotherapy to treat patients 
with breast cancer defective in BRCA1 and/or BRCA2 is 
a clear example of what is known as synthetic lethality 
[19, 20]. So far, there is no evidence of BRCA1/BRCA2 
mutations in ES [21]. However, the use of PARPinh has 
been expanded to tumors harboring ETS translocations, 
such as prostate cancer and ES [5, 6]. In ES in particular, 
sensitivity to PARPinh seems to be related to EWSR1-
FLI1 transcriptional activity [6, 7]. 
Olaparib is the drug chosen in most studies 
addressing ES [6, 7, 22]. In the present study, we decided 
to test the efficacy of three different PARPinh, all of 
them extensively studied in solid tumors. Olaparib and 
Veliparib have a similar mechanism of action in that they 
compete with nicotinamide adenine dinucleotide (NAD) 
to bind the catalytically active site of the PARP enzyme. 
By contrast, Iniparib (BSI-201) does not compete with the 
active site of the PARP enzyme but induces an irreversible 
modification of PARP1 and stimulates a PARP1-protease 
[23]. Although Iniparib was tested in a phase III study 
in triple-negative breast cancer patients, its efficacy and 
specificity have recently been questioned [24]. According 
Figure 6: Immunofluorescence and Immunohistochemical analysis of tumor xenografts: Apoptosis, proliferation and 
DNA damage induction. A. The images show a higher number of Ki67 positive cells in the control group as compared to tumors treated 
with Trabectedin alone or with the combinations of Olaparib and Trabectedin (central panel). In the TUNEL assay, cell staining was mostly 
observed in tumors from the Trabectedin group and from the combination groups (upper panel). PARP cleavage only revealed a slight 
staining in the Olaparib group. b. The images show intranuclear γH2AX staining in tumors from all the groups but it is more extensive and 
intense mainly in non-necrotic areas of the tumors from the Olaparib and Trabectedin combinations. c. The images show an intense, focal 
BRCA2 staining in tumors from the Trabectedin and the combination groups. Very little expression was observed in the Olaparib group. 
Combination1 refers to 100mg/kg Olaparib and 0.15mg/kg Trabectedin, which started to be administered after day 7. Combination2 refers 
to Olaparib and 0.15mg/kg.Trabectedin.
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to the results of our study, Iniparib is by far the least 
active of the three PARPinh tested. By contrast, Olaparib 
was the most active compound tested against ES cell 
lines, with an IC50 for proliferation ranging from the high 
nanomolar to the low micromolar range, very similar to 
the data published by other groups [7]. Interestingly, and 
in contrast to previous work [7], Olaparib was seen to 
be not only a potent cytotoxic agent after 3 days of drug 
exposure, but its action lasted for at least 6 days, when the 
IC50 underwent a significant decrease in all the cell lines 
assayed. However, in the in vivo study, Olaparib alone 
was only partially effective in terms of tumor shrinkage. 
This is also in accordance with previous studies, in which 
Olaparib was not able to halt tumor growth [6]. In fact, a 
recent clinical trial of Olaparib alone in relapsed/refractory 
ES patients was withdrawn due to the lack of objective 
responses (Revised in [1]). 
 Since PARPinh are not only used in monotherapy 
but also in combination with radiotherapy and other 
chemotherapeutic agents that cause DNA damage, 
we decided to combine Olaparib with Trabectedin. 
Interestingly, the groups of Grohar and Burdach have 
recently suggested combining Trabectedin with drugs that 
further increase DNA damage and diminish EWSR1-FLI1 
transcriptional activity. According to the hypothesis of 
Grohar and Burdach, the repression of the downstream 
targets of an oncogene increases cancer cell sensitivity; 
such repression can be specifically addressed by combined 
precision chemotherapy, increasing the therapeutic index 
of the combined agents and overcoming resistance to 
highly selective targeted therapies [14, 25]. Grohar et al. 
demonstrated that the combination of Trabectedin and 
Irinotecan in ES exhibits synergistic activity, confirming 
the molecular precision treatment concept [14, 25]. 
This concept could also be applied to the combination 
of PARPinh and Trabectedin. In fact, PARPinh, and in 
particular Olaparib, are involved in DNA damage, and 
the knockdown of PARP1 in ES cell lines disrupts the 
expression of known EWSR1-FLI1 target genes [6]. 
Grohar et al. found a decreased expression of known 
Figure 7: tumor growth A. and animal survival b. of HSJD-ES-004 and HSJD-ES-006 PDX models upon single-agent and combination 
therapies. Olaparib and Trabectedin in combination induced complete tumor regression A. and improved overall survival b. in both PDX 
models as compared with single treatments and controls.
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EWSR1-FLI1 up-regulated target genes, such as NR0B1, 
and very little expression of down-regulated target genes 
after treatment with Trabectedin at 10nM for 12 hours in 
TC71 and TC32 ES cells [12]. Our results showed that 
the combination of Trabectedin and Olaparib was highly 
synergistic, increasing apoptotic activity and arresting the 
cell cycle at the G2/M phases for ES, but that it did not 
deregulate EWSR1-FLI1 target expression in the TC71 
cell line. This antitumor activity was also observed in 
vivo, where the drug combination reduced tumor growth 
dramatically, even when Trabectedin was administered one 
week later than Olaparib. Furthermore, we observed that 
although both agents alone induced DNA damage through 
an accumulation of γH2AX foci and deregulation of the 
DDR pathways in vitro, the combination significantly 
increased this phenomenon. This drug combination 
actively deregulated the major DDR pathways, without 
changing EWSR1-FLI1 target expression. The effects of 
the drug combination in vivo confirmed the in vitro data, 
the accumulation of γH2AX foci increasing with the 
overexpression of BRCA2. Most importantly, a complete 
and maintained regression of tumors for 80 days due to the 
combination therapy was observed in ES PDX models. To 
our knowledge, this is the first time PDX mouse models 
have been reported in ES. These models are renewable 
tumor models engrafted in mice from fresh human ES 
samples without prior in vitro growth. PDX models have 
been shown to be biologically stable and to accurately 
reflect patient tumor biology and treatment response 
in other tumor types [26, 27]. Thus, the results of our 
study could be considered sufficient to justify the design 
of a clinical trial using the combination of Olaparib and 
Trabectedin in ES. Other studies have combined Olaparib 
with drugs/strategies inducing DNA damage, namely 
Temozolomide and radiotherapy [6, 22]. In both cases 
the combination regimen showed a reduction in tumor 
volume in comparison with the controls. However, DNA 
damage induction and the DDR activation machinery were 
not studied in depth. Here, we observed not only that the 
combination is active both in vitro and in vivo but also 
that it induces a deregulation of the DDR pathways. A 
recent study has shown that ES cell lines are defective in 
DDR and when the PARPinh BMN-673 was combined 
with Irinotecan and Temozolomide, 88% of complete 
responses were achieved in an orthotopic model of ES 
[10]. In our study, complete responses were achieved with 
the combination of Olaparib and Trabectedin in 100% of 
mice from two ES PDX models studied. 
In conclusion, to the best of our knowledge this 
is the first time that the combination of a PARPinh and 
Trabectedin has been reported in ES. The combination 
could be a useful therapeutic strategy in ES that should be 
further explored. 
MAtErIALs AND MEtHODs
cell culture
Ten ES cell lines (RDES, WE68, STAET-2.1, RM82, 
TC71, SK-N-MC, CADO, A673, A4573, STAET-1) and 
the SJRH Rhabdomyosarcoma cell line were grown in 
RPMI supplemented with 10% Fetal Bovine Serum (FBS) 
and 1% antibiotic (P/S), except that A673 ES cell line was 
grown in DMEM supplemented with 10% FBS (Gibco, 
Invitrogen). All ES cell lines were obtained from the FP6-
funded Eurobonet consortium cell line panel, which is 
maintained and regularly checked and characterized [4]. 
All ES cell lines and SJRH were grown on gelatin-coated 
plates in an incubator at 37ºC and 5% CO2. MCF7 and 
MDA-MB-231 breast cancer cell lines were cultured in 
DMEM medium supplemented with 10% Fetal Bovine 
Serum (FBS) and 1% antibiotic (P/S) (Gibco, Invitrogen) 
and 1% glutamine (Gibco, Invitrogen). All cells were free 
of mycoplasma, as screened at least once a month with the 
MycoAlert® Mycoplasma Detection Kit (Lonza). 
Drugs
The following PARPinh were used: Olaparib (LC 
Laboratories), Veliparib (AxonMEDCHEM), Iniparib (LC 
Laboratories). All drugs were prepared at the appropriate 
stocking concentration in DMSO (Sigma) and stored at 
-20ºC until use. Trabectedin was kindly provided by 
PharmaMar (Madrid, Spain).
Proliferation assays
Briefly, cells were counted by Trypan blue and 
seeded 24 hour prior to treatment in complete medium on 
24-well culture plates or 96-well culture plates. Treatments 
were added later and cells were incubated for 72 hours. 
The medium was then removed and cells were incubated 
for 1h with a 1:10 MTT solution (Sigma-Aldrich). The 
medium was later removed and replaced by 500µl of 
DMSO (Merck). Absorbance was then read on an Infinite® 
F500 Tecan plate reader (Tecan) at 570nm. The number of 
cells seeded for each assay depended on the type of cell 
line and its growth rate. To define drug-drug interactions 
(in terms of synergism, additivity, or antagonism), the CI 
was calculated according to the Chou-Talalay method 
[15, 16], using CalcuSyn software Version 2.0 (Biosoft). 
Synergy levels can be broadly divided into: < 0.1 very 
strong synergism; 0.1-0.90, synergism (ranging from 
strong synergism to slight synergism), and 0.90-1.10, 
nearly additive to additive.
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Detection of caspase 3 and 7 activities
The activity of caspases 3 and 7 was determined in 
a Caspase Glo (Promega) luminescence assay. Initially, 
cells were seeded in white-walled 96-well plates for 24 
hours and then treated with the drug for 24 hours. After 
incubation with the drug, 100µl of a mixture of caspase 
Glo buffer and substrate, prepared at the time at RT, was 
added per well. Plates were incubated for 1 hour and 
luminescence was read on an Infinite® F500 Tecan plate 
reader (Tecan). Caspase 3 and 7 activity was calculated 
by subtracting the blank value (well with medium but no 
cells) and was normalized to the controls (untreated cells). 
PArP1 probe design and FIsH
Two specific and independent PARP1 locus probes 
(BAC Clones RPII-964L17 and RPII-831N20) labeled 
with Spectrum green-dUTP (green signal) (Vysis) were 
made. Probes were labeled as previously described 
[28, 29]. Briefly, isolated BAC DNA was labeled with 
Spectrum red-dUTP (Vysis) by nick translation (Vysis) 
and purified after adding 10μg of COT-1. A commercially 
available (CEP 1) probe (Vysis) labeled with spectrum 
red (red signal) was also used. To check the specificity 
of the home-made probes, co-hybridizations using both 
commercial CEP1 and PARP1 specific probes were 
performed on peripheral blood cells in metaphase. FISH 
analysis was performed on cell lines fixed in methanol-
acetic acid. A volume of 10μl of the diluted probes 
was applied to the slides. The slide was covered with a 
glass coverslip and sealed with rubber cement. Using a 
Hybrite machine (Vysis), denaturation was performed 
at 75°C for 5 minutes and hybridization was carried 
out at 37°C for at least 16 hours. After removing the 
coverslips, post-hybridization washes were done at 46ºC 
in 2XSSC, 50% formamide, for 5 minutes and stained 
with DAPI (6-diamidino-2-phenylindole) and mounted 
with Vectashield H-1000 medium (Vector). Digital images 
were obtained using a Zeiss Axioplan2 epi-fluorescence 
microscope (Carl Zeiss) equipped with a digital camera 
(ORCA-ER-1394, Hamamatsu Photonics KK). In all 
cases, one hundred nuclei were counted [28, 30]. 
Protein extraction and western blotting
Protein extraction and western blotting were done as 
previously described [31, 32]. Briefly, primary antibodies 
were used: pH2Ax (Cell Signaling); PARP (Cell 
signaling), Calnexin (Santa-Cruz) and Actin (Sigma) were 
incubated overnight at 4ºC in TBS-T 0.5% BSA (Sigma). 
Secondary anti-Rb-Cy3 and anti-Ms-Cy5 antibodies were 
incubated for 1 hour at RT and the images were recovered 
using Odissey software. The quantification of protein 
levels was accomplished using Image J software (National 
Institutes of Health).
Immunofluorescence
Cells were seeded on slide covers placed (one slide 
cover per well) on 96-well plates pretreated with 1% 
gelatin/ MilliQ H2O (Sigma) for 24 hours in complete 
medium. The medium was removed and the cells were 
incubated in medium with drug/DMSO (Sigma) for 6 
hours (short exposure) or 24 hours (long exposure). After 
treatment, cells were fixed in ice-cold methanol (Sigma) 
for 15 minutes, washed twice, permeabilized with 0.1% 
Triton X-100 for 30 minutes, and blocked in PBS with 
2% BSA (Sigma) for another 30 minutes. The pH2AX 
primary antibody (Cell Signaling) was then incubated 
overnight, and after several washes the Cy3 secondary 
antibody (Jackson ImmunoResearch) was incubated for 
1 hour. After 15 minutes of washes, the primary anti-
53BP1 antibody (Abcam) was incubated for 3 hours at 
RT followed by several washes, and the Cy5 secondary 
antibody was incubated for 1 hour at RT. After several 
washes, DAPI at 1mg/ml in PBS was used to stain 
nuclei, applying it for 15 minutes. Finally, slide covers 
were mounted using Mowiol (Sigma) and were observed 
under a Leica microscope using Leica software. pH2AX 
fluorescence was quantified using Image J software, where 
at least 50 nuclei were analyzed using the following 
formula: Corrected Total Cell Fluorescence (CTCF) = 
Integrated Density (IT)- (Area of selected cell- Mean of 
fluorescence of background readings). The number of 
intracellular foci of pH2AX was measured by counting 
independent intranuclear foci of at least 50 nuclei.
real time rt-Pcr
RNA was extracted from all cell lines studied 
using a Qiagen mini kit (Qiagen). Following Qiagen’s 
instructions, 2μg of high quality RNA was reverse-
transcribed (Qiagen). Primers for the PARP1 gene were 
designed using primer 3 software (MIT, Cambridge, 
MA, USA), and quantitative reverse transcription-
PCR (qRT-PCR) was performed as described earlier 
using SYBR Green [32]. qRT-PCR was performed 
under universal cycling conditions on an ABI 7300HT 
instrument (Applied Biosystems), using commercially 
available TaqMan probes: PARP1 (HS00242302-m1); 
NR0B1 (HS03043658-m1); NKX2-2 (HS00159616-m1); 
TGFβR2 (HS00234253-m1); CAV1 (HS00971716_m1) 
and Mastermix (all from Life Technologies). Cycle 
threshold (CT) values were normalized to Beta Actin 
(ACTB). Experiments were performed at least twice and 
in triplicate. The relative expression level was calculated 
as described previously [33]. 
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 Low-density microarrays
RNA was extracted from the TC71 cell line, 
using a Qiagen mini kit (Qiagen). Following Qiagen’s 
instructions, 0.5μg of high-quality RNA were reverse-
transcribed and hybridized on a Human DNA Repair 
PCR Array (Qiagen). The following protocol was set 
in an iQ5 BioRad thermo cycler (Bio-Rad): 10 minutes 
cycle at 95ºC for Taq Polymerase activation, followed by 
40 cycles of 15 seconds at 95ºC and 1 minute at 60ºC to 
perform fluorescence data acquisition. Data were analyzed 
using the online software http://www.sabiosciences.
com/pcrarraydataanalysis.php. Pathway analysis was 
performed using IPA (Ingenuity systems), as previously 
described [32].
cell cycle
Propidium iodide (PI) staining was used to analyze 
cell cycle changes by Fluorescence-Activated Cell Sorting 
(FACS). Cells were seeded in 6 well-plates and incubated 
with the appropriate drug for 24 hours. PI staining was 
performed as described elsewhere [31, 32]. Cells were 
acquired (20,000 events) with a FACSort Cytometer 
(Becton Dickinson). Analysis of the results was performed 
using Infinicyt (Cytognos), Paint-a-Gate (Becton 
Dickinson) and ModFit software (Verity Software House).
Migration assays
These assays were performed by wound healing, 
where 5 x104 cells were seeded in 24-well plates and when 
confluence reached 90%, a wound was performed with a 
pipette tip from one side to the other. Medium with drug 
was added and incubated for 8/24/48 and/or 72 hours. 
After drug exposure, cells were washed, stained with 1% 
crystal violet (Sigma-Aldrich) in 2% ethanol (Sigma-
Aldrich), and observed with a Leica Microscope (Leica 
Microsystems), where pictures were obtained. 
In vivo study
4-5 week-old female NOD/scid mice were used. 
Induction of tumour xenografts was performed by 
subcutaneous injection of cell suspensions, containing 
5x106 of TC71 live cells in 0.2 ml of 1:1 cellular medium/
Matrigel matrix (Becton Dickinson) into the right flank of 
the mice. This study followed the Spanish and European 
Union guidelines for animal experimentation (RD 
1201/05, RD 53/2013 and 86/609/CEE, respectively). 
Mice were randomized into control and treatment groups 
(n = 10) one week after the tumor started to be measurable 
(10 days after injection: day 0 of treatment). Drugs were 
administered in the following vehicles: 0.9% NaCl in 
sterile water, vehicle of Trabectedin and/or 2-hydroxyl-
propyl-B cyclodextrin 10% in PBS plus 10% DMSO 
(Sigma-Aldrich), vehicle of Olaparib. Mice with tumor 
volumes greater than 1.5 cm3 were excluded from the 
analysis. Tumors were measured every 2-3 days with a 
caliper and diameters were recorded. Tumor volumes were 
calculated using the formula: a2b/2, where a and b are the 2 
maximum diameters. Mice were sacrificed by anaesthetic 
overdosing 4 weeks after cell injection, and tumors, liver 
and kidneys were collected for histopathological analyses. 
All experimental manipulations with mice were performed 
under sterile conditions in a laminar flow hood.
In vivo preclinical testing in Es PDX models
NOD/SCID mice (Harlan, Barcelona, Spain) were 
used for initial engraftment and further passages were 
performed in athymic nude mice (Harlan). For the survival 
studies, nude mice bearing subcutaneous 200-500 mm3 
tumors in both flanks were randomized into 4 groups of 
5 mice. One group received 100 mg/kg Olaparib twice 
daily (5 days on, 2 off) IP for 2 weeks; a second group 
was treated with 0.15 mg/kg Trabectedin (the MTD) IV 
on days 1 and 8; a third group received the combination of 
Olaparib and Trabectedin under the same regimens; and a 
fourth group acted as controls. Mice were sacrificed when 
the tumor diameter reached 1.5 cm3 and the study was 
finalized at day 80 post-treatment. 
To study the activity of the different regimens, we 
evaluated tumor response at the end of treatment (day 21) 
and animal survival until the end of the study (day 80). 
Tumor response was evaluated as described elsewhere 
[34]. Animal survival was defined as the time interval 
between the initial date of treatment and the date on which 
the threshold 1.5 cm3 tumor volume was reached. 
Histopathology and immunohistochemistry
Excised tumors, kidney and livers were sampled just 
after sacrifice and representative areas were a) formalin-
fixed (24 hours) (Millipore) and paraffin-embedded and 
(b) snap-frozen in OCT and stored at 80ºC as previously 
described [32]. Tissue sections 2μM thick were stained 
with hematoxilin & eosin and prepared for IHC. Two 
experienced pathologists (MCGM and EDA) observed the 
samples under a Leica microscope (Leica Microsystems). 
IHC was performed as previously described [32] using the 
following primary antibodies: anti-pH2AX (Millipore); 
anti-cleaved PARP (cell signaling); anti-Ki67 (Millipore) 
and anti-BRCA2 (Millipore). TUNEL assays (Roche) 
were performed to detect DNA fragmentation and late 
apoptosis. To quantify the extent of necrosis and the IHC 
findings, the Dotslide analysis program (Olympus) and 
the Ariol Image analysis system (Olympus) were used 
respectively. 
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statistical analysis and bio software
Analysis of the low-density micro arrays was 
performed using the online software http://www.
sabiosciences.com/pcrarraydataanalysis.php. IC50 values 
were calculated from linear transformation of the dose-
response curves. Differences among groups were analyzed 
with the Mann–Whitney U-test, Student’s t test or 
ANOVA. Median survivals were calculated using Kaplan-
Meier curves and the log-rank test was used for statistical 
comparisons between each treatment group and the control 
group (Graphpad Prism 5 software). Significance was 
considered when p < 0.05.
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